Patients 40kg body weight ≥ Moderate CD Severe CD Frequency Induction 160 mg 160 mg Initial Dose (Day 0) as four 40mg injections OR as two 40mg injections on Day 0 and two 40mg injections on Day 1 80mg 80mg Second Dose (Day 14) as two 40mg injections Maintenance 20mg 40mg Starting Day 28 & continuing fortnightly Some patients may benefit from increasing the frequency to weekly if a disease flare or an inadequate response is experienced during maintenance dosing. Continued therapy should be carefully considered in a subject not responding by week 12. Good nutrition should be encouraged alongside pharmacological therapy to allow appropriate growth. Ulcerative colitis Dose Frequency Induction 160 mg Initial Dose (Day 0) as four injections OR as two injections on Day 0 and two injections on Day 1 80mg Second Dose (Day 14) as two injections Maintenance 40mg Starting Day 28 & continuing fortnightly During maintenance treatment, corticosteroids may be tapered in accordance with clinical practice guidelines. Some patients who experience decrease in their response may benefit from an increase in dosing frequency to 40 mg Humira every week. Humira should not be continued in patients who do not achieve a clinical response in the first 8 weeks of treatment. Efficacy of Humira in the treatment of ulcerative colitis has not been demonstrated in patients who've failed previous anti-TNF therapy (see CLINICAL TRIALS). Psoriasis The recommended dose of Humira for adult patients is an initial dose of 80 mg, followed by 40 mg fortnightly, starting one week after the initial dose. Preparation of Humira Humira is intended for use under the guidance and supervision of a physician. Patients may self-inject Humira if their physician determines that it is appropriate and with medical follow-up, as necessary, after proper training in subcutaneous injection technique. Sites for self-injection include thigh or abdomen. Injection sites should be rotated. New injections should never be given into areas where the skin is tender, bruised, red or hard. Parenteral drug products should be inspected visually for particulate matter and discolouration prior to administration, whenever solution and container permit. Humira should not be mixed in the same syringe or vial with any other medicine. Any unused product or waste material should be disposed of in accordance with local requirements. Humira contains no antimicrobial agent. Discard any residue.
Patients ≥ 40kg body weight Moderate CD Severe CD Frequency Induction 160 mg 160 mg Initial Dose (Day 0) as four 40mg injections OR as two 40mg injections on Day 0 and two 40mg injections on Day 1 80mg 80mg Second Dose (Day 14) as two 40mg injections Maintenance 20mg 40mg Starting Day 28 & continuing fortnightly Some patients may benefit from increasing the frequency to weekly if a disease flare or an inadequate response is experienced during maintenance dosing. Continued therapy should be carefully considered in a subject not responding by week 12. Good nutrition should be encouraged alongside pharmacological therapy to allow appropriate growth. Ulcerative colitis Dose Frequency Induction 160 mg Initial Dose (Day 0) as four injections OR as two injections on Day 0 and two injections on Day 1 80mg Second Dose (Day 14) as two injections Maintenance 40mg Starting Day 28 & continuing fortnightly During maintenance treatment, corticosteroids may be tapered in accordance with clinical practice guidelines. Some patients who experience decrease in their response may benefit from an increase in dosing frequency to 40 mg Humira every week. Humira should not be continued in patients who do not achieve a clinical response in the first 8 weeks of treatment. Efficacy of Humira in the treatment of ulcerative colitis has not been demonstrated in patients who've failed previous anti-TNF therapy (see CLINICAL TRIALS). Psoriasis The recommended dose of Humira for adult patients is an initial dose of 80 mg, followed by 40 mg fortnightly, starting one week after the initial dose. Preparation of Humira Humira is intended for use under the guidance and supervision of a physician. Patients may self-inject Humira if their physician determines that it is appropriate and with medical follow-up, as necessary, after proper training in subcutaneous injection technique. Sites for self-injection include thigh or abdomen. Injection sites should be rotated. New injections should never be given into areas where the skin is tender, bruised, red or hard. Parenteral drug products should be inspected visually for particulate matter and discolouration prior to administration, whenever solution and container permit. Humira should not be mixed in the same syringe or vial with any other medicine. Any unused product or waste material should be disposed of in accordance with local requirements. Humira contains no antimicrobial agent. Discard any residue.
auspar-adalimumab-140805-pi.docx